New cocktail aims to outsmart pancreatic Cancer's defenses

NCT ID NCT05077800

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combination. The main goal is to see if this approach improves the time before the cancer progresses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Charlestown, Massachusetts, 02129, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

  • University of Washington School of Medicine

    Seattle, Washington, 98109, United States